Aclaris Therapeutics, Inc. (ACRS)
PHARMACEUTICAL PREPARATIONS
Aclaris Therapeutics, Inc. (ACRS) is listed on Nasdaq, where it has traded since October 7, 2015.
- Listed On
- Nasdaq
- Listed Since
- October 7, 2015
- Employees
- 73
- Market Cap
- $619M
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 144 institutions reported holding ACRS, with 118.9 million shares worth $628.9 million in aggregate. The largest reported holder was RA Capital Management, with 12.7 million shares worth $67.3 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management | 12,723,026 | $67M | Added 86.99% |
| Bml Capital Management | 11,975,000 | $63M | Reduced 15.96% |
| BlackRock | 10,037,008 | $53M | Added 35.51% |
| Deep Track Capital | 9,345,000 | $49M | Unchanged |
| Vanguard | 8,335,521 | $44M | Added 10.57% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ACRS?
Aclaris Therapeutics, Inc. (ACRS) is listed on Nasdaq, where it has traded since October 7, 2015.
Who are the largest institutional holders of ACRS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ACRS were RA Capital Management, Bml Capital Management and BlackRock.
How many institutions own ACRS?
144 institutions reported a position in ACRS for the quarter ended June 30, 2026, worth $628.9 million in total.
Did institutions buy or sell ACRS last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ACRS.
Every reported institutional holder, plus insider and congressional trades in ACRS, on SentiSense.